CRL 1072

Drug Profile

CRL 1072

Latest Information Update: 18 May 2001

Price : $50

At a glance

  • Originator CytRx Corporation
  • Class Antibacterials; Antivirals; Surfactants
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Hepatitis B; Herpes simplex virus infections

Most Recent Events

  • 18 May 2001 An animal study has been added to the Bacterial infections pharmacodynamics section
  • 28 Dec 2000 CRL 1072 is available for licensing (
  • 28 Dec 2000 Discontinued-Preclinical for Hepatitis B in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top